Chemical and pharmaceutical plant "Akrikhin" JSC

AKRIKHIN

Contacts

Address: 142450, Russia, Moscow region, Noginsky district, Staraya Kupavna, st. Kirova, 29 Tel./fax, 702-95-03 E-mail Official website: https://www.akrikhin.ru

About the company

The company was founded in 1936.

JSC Chemical and Pharmaceutical Plant AKRIKHIN (JSC AKRIKHIN) is one of the leading Russian pharmaceutical companies producing affordable, effective and high-quality medicines. The company is among the top 5 largest local pharmaceutical manufacturers in terms of sales and production volume on the Russian pharmaceutical market.

JSC AKRIKHIN produces a wide range of socially significant drugs, making its contribution to the development of the Russian healthcare system. The company is one of the largest Russian manufacturers of drugs included in the List of Vital and Essential Medicines (VED), as well as drugs for the treatment of tuberculosis and diabetes.

The production complex of AKRIKHIN JSC is located 20 km from Moscow. The company's production includes workshops for the production of medicines of almost all forms: tablets, capsules, liniments, ointments, creams, syrups, gels, suppositories, etc. The company's annual production volume is more than 60 million packages. Medicines are produced on foreign equipment from high-quality raw materials based on the latest technologies. The modern warehouse complex of the enterprise has more than 4.5 thousand pallet spaces, ensuring proper storage of medicines.

Manufactured products

The company produces more than 150 drugs of various dosage forms: tablets, capsules, ointments, suppositories, creams, syrups. AKRIKHIN concentrates on therapeutic areas of high social significance, i.e. most in demand by the Russian healthcare system: cardiology, diabetes mellitus, neurology, dermatology, tuberculosis, gynecology, pediatrics.

History of the enterprise

1936 Foundation of the company. The first industrial batch of the drug Akrikhin for the treatment of malaria was released, which gave the name to the enterprise and made it possible to quickly eliminate such a dangerous disease as malaria.

1950-1990. The enterprise was one of the main production facilities of pharmaceutical substances in the Soviet Union, providing 24% of the volume of substances produced in the country.

1992 The enterprise was transformed into an open joint stock company. A decision was made to repurpose the enterprise’s work from the chemical synthesis of substances to the production of finished medicines.

2007 Beginning of a strategic partnership with the Polish pharmaceutical company Polpharma. The partnership involves close cooperation between companies in the development, production, promotion and distribution of medicines.

Links:

Official website of JSC "AKRIKHIN"

Carvedilol-Akrikhin

Chronic heart failure.

In patients with heart failure, during the period of dose selection of the drug Carvedilol-Akrikhin, an increase in symptoms of chronic heart failure or fluid retention may be observed. If such symptoms occur, it is necessary to increase the dose of diuretics and not increase the dose of Carvedilol-Akrikhin until hemodynamic parameters stabilize.

Sometimes it is necessary to reduce the dose of Carvedilol-Akrikhin or, in rare cases, temporarily discontinue the drug. Such episodes do not prevent further correct selection of the dose of the drug Carvedilol-Akrikhin.

Carvedilol-Akrikhin is used with caution in combination with cardiac glycosides (excessive slowing of AV conduction is possible).

Kidney function in chronic heart failure

When Carvedilol-Akrikhin was prescribed to patients with heart failure and low blood pressure (systolic blood pressure less than 100 mm Hg), coronary heart disease and diffuse vascular changes and/or renal failure, a reversible deterioration in renal function was observed. The dose of the drug is selected depending on the functional state of the kidneys.

COPD

For patients with COPD (including bronchospastic syndrome) who are not receiving oral or inhaled β2-adrenergic drugs, Carvedilol-Akrikhin is prescribed only if the possible benefits of its use outweigh the potential risk. If there is an initial predisposition to bronchospastic syndrome, shortness of breath may develop when taking the drug Carvedilol-Akrikhin as a result of increased airway resistance. At the beginning of treatment and when increasing the dose of Carvedilol-Akrikhin, these patients should be carefully monitored, reducing the dose of the drug when initial signs of bronchospasm appear.

Diabetes

The presence of beta-adrenergic blocking properties of the drug does not exclude the possibility of manifestation of latent diabetes mellitus, decompensation of existing diabetes mellitus, or inhibition of the contrainsular system.

The drug is prescribed with caution to patients with diabetes mellitus, as it may mask or weaken the symptoms of hypoglycemia (especially tachycardia). In patients with heart failure and diabetes mellitus, the use of Carvedilol-Akrikhin may be accompanied by disturbances in glycemic control.

Peripheral vascular diseases

Caution is necessary when prescribing Carvedilol-Akrikhin to patients with peripheral vascular diseases (including Raynaud's syndrome), since beta-blockers may increase the symptoms of arterial insufficiency.

Thyrotoxicosis

Like other beta-blockers, Carvedilol-Akrikhin can reduce the severity of symptoms of thyrotoxicosis.

General anesthesia and major surgery

Caution is required in patients undergoing surgery under general anesthesia, due to the possibility of additive negative effects of the drug Carvedilol-Akrikhin and agents for general anesthesia.

Bradycardia

Carvedilol-Akrikhin can cause bradycardia; if the heart rate decreases to less than 55 beats/min, the dose of the drug should be reduced.

Increased sensitivity

Caution must be exercised when prescribing Carvedilol-Akrikhin to patients with anamnestic indications of severe hypersensitivity reactions or undergoing a course of desensitization, since beta-blockers may increase sensitivity to allergens and the severity of anaphylactic reactions.

Psoriasis

For patients with anamnestic indications of the emergence or exacerbation of psoriasis when using beta-blockers, Carvedilol-Akrikhin can be prescribed only after a thorough analysis of the possible benefits and risks.

Concomitant use of slow calcium channel blockers (SCBCs)

In patients simultaneously taking BMCCs such as verapamil or diltiazem, as well as other antiarrhythmic drugs, it is necessary to regularly monitor ECG and blood pressure.

Pheochromocytoma

Patients with pheochromopytoma should be given an alpha blocker before starting any beta blocker. Although Carvedilol-Akrikhin has both beta and alpha adrenergic blocking properties, there is no experience with its use in such patients, so it should be prescribed with caution to patients with suspected pheochromocytoma.

Prinzmetal's angina

Non-selective beta-blockers may cause pain in patients with Prinzmetal's angina. There is no experience in prescribing Carvedilol-Akrikhin to these patients. Although its alpha-blocking properties may prevent such symptoms, carvedilol should be used with caution in such cases.

Contact lenses

Patients who wear contact lenses should be aware of the possibility of reducing the amount of tear fluid.

Withdrawal syndrome

Treatment with Carvedilol-Akrikhin is long-term. It should not be stopped abruptly, but the dose of the drug should be gradually reduced at weekly intervals. This is especially important in patients with coronary heart disease.

If it is necessary to perform surgery using general anesthesia, it is necessary to warn the surgeon/anesthesiologist about previous therapy with Carvedilol-Akrikhin.

During the treatment period, alcohol consumption is excluded.

Buy Akriderm cream 30g in pharmacies

Buy Akriderm in pharmacies Akriderm in the medicine directory

DOSAGE FORMS cream for external use 0.05%

MANUFACTURERS Akrikhin HFC (Russia)

GROUP Drugs with glucocorticosteroid activity

COMPOSITION Active substance - betamethasone.

INTERNATIONAL NON-PROPENTED NAME Betamethasone

SYNONYMS Beloderm, Betazon, Betakortal, Betliben, Betnovate, Valoderm, Diprolene, Diprospan, Flosteron, Celederm, Celestoderm-B, Celeston

PHARMACOLOGICAL ACTION Anti-inflammatory, glucocorticoid, antiallergic, antipruritic. When applied topically, it constricts blood vessels, relieves itching, reduces the release of inflammatory mediators, interleukins 1 and 2, interferon gamma, inhibits the activity of hyaluronidase and reduces the permeability of the vascular wall. Increases blood glucose levels, accelerates protein catabolism, and retains sodium and water. After parenteral and enteral administration, it is rapidly absorbed. The maximum effect when taken orally develops after 1-2 hours. Easily passes histohematic barriers, including placental ones. Biotransformed in the liver (mainly), the resulting metabolites are not active. Excreted by the kidneys; partially excreted in breast milk.

INDICATIONS FOR USE Congenital adrenal hypoplasia, adrenal insufficiency; shock (anaphylactic, endotoxic, hemodynamic); thyroiditis, thyrotoxic crisis, hypercalcemia due to malignant neoplasms; acute rheumatic carditis, rheumatoid arthritis in the acute phase, systemic lupus erythematosus, scleroderma and other systemic connective tissue diseases, inflammatory lesions of joints and soft tissues, including periarticular (traumatic arthritis, acute gouty and other origins, osteoarthritis, osteochondritis, bursitis, fibrositis , tendonitis, tendovaginitis, tenosynovitis, ankylosing spondylitis, myositis); nephrotic syndrome; prevention of transplant rejection; severe allergic reactions; bronchial asthma, sarcoidosis, berylliosis, Loeffler's syndrome, aspiration pneumonitis; cerebral edema (traumatic, postoperative, metastatic, post-stroke); neurodermatitis, eczema (infantile, atopic, coin-shaped), diaper rash, dermatitis (simple, exfoliative, solar, seborrheic, radiation, bullous herpetiformis, contact, atopic, lower extremities with circulatory failure and others), psoriasis, localized baldness, colloid scars, itching (senile, anogenital), Hyde's nodular prurigo, erythema multiforme exudative, mycosis fungoides, erythroderma, pemphigus and other skin diseases; nonspecific ulcerative colitis, Crohn's disease; recurrent aphthous stomatitis; anemia, idiopathic and secondary thrombocytopenia in adults, acute leukemia in children, lymphoma (Hodgkin, non-Hodgkin), chronic lymphocytic leukemia; breast cancer, prostate cancer; allergic conjunctivitis and corneal ulcer, iritis, iridocyclitis, keratitis, chorioretinitis, diffuse choroiditis, retrobulbar neuritis, prevention of distress syndrome in newborns, croup in diphtheria, tuberculous meningitis, tetanus (in combination with antimicrobial agents).

CONTRAINDICATIONS Hypersensitivity, systemic mycoses, HIV infection, active forms of tuberculosis, chicken pox, herpes simplex (including eyes, oral cavity) and other viral diseases, vaccination period, peptic ulcer of the stomach and duodenum (in the acute phase) , peptic ulcers of the gastrointestinal tract, gastritis, diverticulitis, esophagitis, fresh intestinal anastomoses, congestive heart failure, thrombophlebitis, arterial hypertension, diabetes mellitus, Itsenko-Cushing's disease, osteoporosis, myasthenia gravis, hypoalbuminemia, severe dysfunction of the liver and kidneys, psychoses, open-angle glaucoma, pregnancy, lactation; intra-articularly, into the lesion: unstable joints, previous arthroplasty, infected lesions, periarticular infection, blood clotting disorders; externally: acne, primary viral, fungal, bacterial, incl. tuberculosis, skin and scalp infections; in children under 1 year of age, rash (against the background of diaper rash), dermatitis and dermatoses.

SIDE EFFECTS Hypokalemia, muscle weakness, myopathy, osteoporosis, spontaneous fractures, arterial hypertension, myocardial dystrophy, arrhythmias, thrombosis and thromboembolism, erosive and ulcerative lesions of the gastrointestinal tract, steroid diabetes, decreased immunity and activation of infectious diseases, suppression of the hypothalamic-pituitary-adrenal system, the appearance hirsutism and acne, irregular menstruation, Itsenko-Cushing syndrome, weight gain, agitation or depression, anxiety, psychosis, sleep disturbances, euphoria, glaucoma, cataracts, steroid exophthalmos, withdrawal syndrome; rarely - sodium and water retention (edema); locally - itching, hyperemia, burning, dryness, pigmentation disorders, dermatitis (perioral, allergic), maceration and atrophy of the skin, stretch marks, prickly heat, secondary infections of the skin and mucous membranes.

INTERACTION Liver enzyme inducers reduce therapeutic and toxic effects, estrogens and oral contraceptives enhance them; digitalis glycosides, diuretics (causing potassium deficiency), amphotericin B, carbonic anhydrase inhibitors - increase the likelihood of arrhythmias and hypokalemia; alcohol and NSAIDs may cause a risk of ulcerative-erosive lesions or bleeding in the gastrointestinal tract; immunosuppressants - the likelihood of infections and the development of lymphomas and other lymphoproliferative diseases; ritodrine - the possibility of pulmonary edema in pregnant women. Betamethasone weakens the hypoglycemic activity of antidiabetic agents and insulin, the natriuretic and diuretic activity of diuretics, and the activity of vaccines (due to decreased antibody production); anticoagulation - derivatives of coumarin and indanedione, heparin, streptokinase and urokinase. Increases the hepatotoxicity of paracetamol. Reduces the concentration of salicylates and mexiletine in the blood.

METHOD OF APPLICATION AND DOSAGE The cream is applied in a thin layer to the affected areas of the skin 2 times a day (morning and evening).

OVERDOSE Symptoms: nausea, vomiting, sleep disorders, euphoria, agitation, depression. With long-term use in high doses - osteoporosis, fluid retention in the body, increased blood pressure and other signs of hypercortisolism, including Itsenko-Cushing syndrome, secondary adrenal insufficiency. Treatment: against the background of gradual drug withdrawal, maintenance of vital functions, correction of electrolyte balance, antacids, phenothiazines, lithium preparations; for Itsenko-Cushing syndrome - aminoglutethimide.

SPECIAL INSTRUCTIONS Use with caution in diabetes mellitus, corneal herpes simplex, systemic lupus erythematosus, osteoporosis, in patients at risk of thrombosis, in the elderly, in children, only against the background of appropriate antibacterial therapy - for abscesses, purulent infections, tuberculosis. It is necessary to take into account the increased effect in hypothyroidism, liver cirrhosis, and the likelihood of developing relative adrenal insufficiency. During long-term treatment, one should carefully monitor the dynamics of growth and development in children, periodically conduct an ophthalmological examination, regularly monitor the function of the hypothalamic-pituitary-adrenal system, glucose levels in the blood and urine (especially in patients with diabetes mellitus), electrolytes in the serum, occult blood in feces. During therapy, immunization and drinking alcohol should be avoided.

STORAGE CONDITIONS At a temperature of 15-25 °C.